Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Masson

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Cancer Immunity|July 9, 2013
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanomaJeffrey Weber, Omid Hamid, Asim Amin, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 3, 2006
Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patientsLorenz M Jost, Hans-Peter Gschwind, Tarja Jalava, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2005
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumoursKlaus Mross, Joachim Drevs, Marianne Müller, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 4, 2011
Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humansJiachang Gong, Jinping Gan, Janet Caceres-Cortes, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 17, 2017
Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meetGabriel Helmlinger, Nidal Al-Huniti, Sergey Aksenov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignanciesFrancis Giles, Thomas Fischer, Jorge Cortes, et al.
Leukemia Research|June 15, 2007
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasiaFrancis J Giles, Alan F List, Michael Carroll, et al.
Sensors (Basel, Switzerland)|February 13, 2025
Commissioning an All-Sky Infrared Camera Array for Detection of Airborne ObjectsLaura Domine, Ankit Biswas, Richard Cloete, et al.
Nature Communications|October 22, 2022
Atomically precise control of rotational dynamics in charged rare-earth complexes on a metal surfaceTolulope Michael Ajayi, Vijay Singh, Kyaw Zin Latt, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 25, 2024
2D Ionic Liquid-Like State of Charged Rare-Earth Clusters on a Metal SurfaceDaniel Trainer, Alex Taekyung Lee, Sanjoy Sarkar, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Cancer Immunity|July 9, 2013
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanomaJeffrey Weber, Omid Hamid, Asim Amin, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 3, 2006
Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patientsLorenz M Jost, Hans-Peter Gschwind, Tarja Jalava, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2005
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumoursKlaus Mross, Joachim Drevs, Marianne Müller, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 4, 2011
Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humansJiachang Gong, Jinping Gan, Janet Caceres-Cortes, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 17, 2017
Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meetGabriel Helmlinger, Nidal Al-Huniti, Sergey Aksenov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignanciesFrancis Giles, Thomas Fischer, Jorge Cortes, et al.
Leukemia Research|June 15, 2007
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasiaFrancis J Giles, Alan F List, Michael Carroll, et al.
Sensors (Basel, Switzerland)|February 13, 2025
Commissioning an All-Sky Infrared Camera Array for Detection of Airborne ObjectsLaura Domine, Ankit Biswas, Richard Cloete, et al.
Nature Communications|October 22, 2022
Atomically precise control of rotational dynamics in charged rare-earth complexes on a metal surfaceTolulope Michael Ajayi, Vijay Singh, Kyaw Zin Latt, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 25, 2024
2D Ionic Liquid-Like State of Charged Rare-Earth Clusters on a Metal SurfaceDaniel Trainer, Alex Taekyung Lee, Sanjoy Sarkar, et al.
Pageof 8